EGFR and cancer: AXL overexpression and heterodimerization with non-TAM RTK members such as MET- (42–44), epidermal growth factor receptor- (EGFR) (43, 45–47), HER2- (44, 48) and HER3- (49, 50) mediated transactivation of AXL have been reported in various cancer systems.